TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04403139

Intervention type: DRUG
Group type: OTHER
Intervention: Shingrix
Description: All participants will receive the FDA-approved recombinant zoster (RZV) vaccine (Shingrix) given at the approved dose and schedule.

Intervention type: DRUG
Group type: OTHER
Intervention: Shingrix
Description: All participants will receive the FDA-approved recombinant zoster (RZV) vaccine (Shingrix) given at the approved dose and schedule.
Study: NCT04942600

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MagStim Rapid2 Transcranial Magnetic Simulation
Description: A non-invasive method of brain stimulation
Study: NCT06410378

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Erector Spinae Plane Block
Description: Patient will receive 20 ml of bupivacaine 0.25 % through Erector Spinae Plane Block approach

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Serratus Anterior Plane Block
Description: Patient will receive 20 ml of bupivacaine 0.25 % through Serratus Anterior Plane Block approach.
Study: NCT04782622

Intervention type: DRUG
Intervention: Apatinib+Camrelizumab
Description: Apatinib 250mg po qd+Camrelizumab 200mg ivdrip q14d
Study: NCT06001606

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Shingrix
Description: Shingrix vaccination

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo vaccination
Study: NCT05937477

Intervention type: OTHER
Intervention: Fitbit smartwatch
Description: Patients wear the wearable to check their biomarkers and use the application to assess their quality of life and side effects at one-week intervals.

Intervention type: OTHER
Intervention: Fitbit smartwatch
Description: Patients wear the wearable to check their biomarkers and use the application to assess their quality of life and side effects at one-week intervals.
Study: NCT05427474

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propranolol , gabapentin
Description: The combined therapy of propranolol and gabapentine can prevent the occurrence of paroxysmal sympathetic hyperactivity in traumatic brain injury patients and improve the clinical outcomes in emergency ICU.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propranolol , gabapentin
Description: The combined therapy of propranolol and gabapentine can prevent the occurrence of paroxysmal sympathetic hyperactivity in traumatic brain injury patients and improve the clinical outcomes in emergency ICU.
Study: NCT05328050

Intervention type: OTHER
Intervention: Registry
Description: observational, data collection

Intervention type: OTHER
Intervention: Registry
Description: observational, data collection
Study: NCT06343701

Intervention type: OTHER
Intervention: Implicit motor imagery
Description: Implicit motor imagery is the ability to engage with the projection and manipulation of the body schema from a first-person perspective. Implicit motor imagery skills were evaluated Recognize App Recognize Hand Hand Laterality Task with, developed by NOI group. (http://www.noigroup.com/ Recognise).

Intervention type: OTHER
Intervention: Implicit motor imagery
Description: Implicit motor imagery is the ability to engage with the projection and manipulation of the body schema from a first-person perspective. Implicit motor imagery skills were evaluated Recognize App Recognize Hand Hand Laterality Task with, developed by NOI group. (http://www.noigroup.com/ Recognise).

Intervention type: OTHER
Intervention: Implicit motor imagery
Description: Implicit motor imagery is the ability to engage with the projection and manipulation of the body schema from a first-person perspective. Implicit motor imagery skills were evaluated Recognize App Recognize Hand Hand Laterality Task with, developed by NOI group. (http://www.noigroup.com/ Recognise).

Intervention type: OTHER
Intervention: Explicit motor imagery
Description: In explicit motor imagery, the person simulates a specific motor movement, that is, the individual is aware that she is imagining the movement.Explicit motor imagery skills were evaluated with Movement Imagery Questionnaire for Children (MIQ-C), mental chronometry and box block test.

Intervention type: OTHER
Intervention: Explicit motor imagery
Description: In explicit motor imagery, the person simulates a specific motor movement, that is, the individual is aware that she is imagining the movement.Explicit motor imagery skills were evaluated with Movement Imagery Questionnaire for Children (MIQ-C), mental chronometry and box block test.
Study: NCT05236634

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alpha Blockers
Description: A total of (120) patients with LUTS due to BPH fulfilling the inclusion criteria will be included in this study. Patients will be randomly divided into three groups: Group A: Forty patients with LUTS due to BPH will be given tamsulosin 0.4 mg for 12 weeks. Group B: Forty patients with LUTS due to BPH will be given tadalafil 5 mg for 12 weeks. Group C: Forty patients with LUTS due to BPH will be given combined therapy for 12 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Combined Alpha Blockers and Phosphodiesterase 5 Inhibitors
Description: A total of (120) patients with LUTS due to BPH fulfilling the inclusion criteria will be included in this study. Patients will be randomly divided into three groups: Group A: Forty patients with LUTS due to BPH will be given tamsulosin 0.4 mg for 12 weeks. Group B: Forty patients with LUTS due to BPH will be given tadalafil 5 mg for 12 weeks. Group C: Forty patients with LUTS due to BPH will be given combined therapy for 12 weeks.
Study: NCT03175718

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Incisional Negative Pressure Wound Therapy (INPWT)
Description: A total of 291 patients will be randomized to receive 7 days of Incisional Negative pressure wound dressing. The dressing will be removed 1 week after surgery.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Wound Dressing
Description: A total of 291 patients will be randomized for standard gauze dressing. This dressing requires no pressure and is applied according to the current standard dressing procedures of the institution. The dressing will be changed every 2-3 days.
Study: NCT05852626

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Redistribution of diabetes care between nurses and physicians
Description: It will be proposed that nurses and physician share the clinical care of patients with type 2 diabetes, with complementing actions

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Individualized glycemic target
Description: Define the target of individualized glycemic treatment for patients with the support of a tool on the website, which will encourage the intensification and de-intensification of treatment when appropriate

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Minimum care recomendations
Description: It will be proposed to carry out the minimum necessary assessments that, annually, nurses and physicians must do to ensure the adequacy of quality indicators in the care of diabetes in the PHC

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No intervention
Description: Primary care health teams will follow their rotine care of type 2 diabetes
Study: NCT05016323

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HR19042 Capsules
Description: HR19042 Capsules

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT04069286

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Aroeira
Description: Active Group oral Aroeira (Schinus terebinthifolia Raddi), 1 tablet of 640 mg + 1 placebo capsule, once a day, for a period of 4 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Omeprazole 20Mg Capsule
Description: Comparator Group omeprazole, 1 20mg capsule + 1 placebo tablet, once a day, for a period of 4 weeks.
Study: NCT06370754

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JS001
Description: 240 mg by IV infusionevery 3 weeks (Q3W), given on cycle day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JS001
Description: 240 mg by IV infusionevery 3 weeks (Q3W), given on cycle day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JS001
Description: 240 mg by IV infusionevery 3 weeks (Q3W), given on cycle day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JS001
Description: 240 mg by IV infusionevery 3 weeks (Q3W), given on cycle day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JS001
Description: 240 mg by IV infusionevery 3 weeks (Q3W), given on cycle day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JS001
Description: 240 mg by IV infusionevery 3 weeks (Q3W), given on cycle day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JS004
Description: 200 mg by IV infusion Q3W, given on cycle day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JS004
Description: 200 mg by IV infusion Q3W, given on cycle day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JS007
Description: 3mg/kg by IV infusion Q3W, given on cycle day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JS007
Description: 3mg/kg by IV infusion Q3W, given on cycle day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JS015
Description: 600mg by IV infusion Q3W, given on cycle day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JS015
Description: 600mg by IV infusion Q3W, given on cycle day 1.
Study: NCT06343701

Intervention type: OTHER
Intervention: Explicit motor imagery
Description: In explicit motor imagery, the person simulates a specific motor movement, that is, the individual is aware that she is imagining the movement.Explicit motor imagery skills were evaluated with Movement Imagery Questionnaire for Children (MIQ-C), mental chronometry and box block test.
Study: NCT05498701

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tafamidis free acid tablet (Test)
Description: 12.2 mg tafamidis free acid tablet (Test)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tafamidis free acid tablet (Test)
Description: 12.2 mg tafamidis free acid tablet (Test)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tafamidis meglumine capsule (Reference)
Description: Commercial 20 mg tafamidis meglumine capsule (Reference)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tafamidis meglumine capsule (Reference)
Description: Commercial 20 mg tafamidis meglumine capsule (Reference)
Study: NCT06042686

Intervention type: DEVICE
Group type: OTHER
Intervention: RF Health MAC Device
Description: Using a 2-day counterbalanced, within-subject repeated-measures design, 16 participants wore two mechanical compression devices, the commonly-used Kendall SCD Express 9525 (SCD) and the novel Recovery Force Movement and Compressions Device (RF-MAC) for 1 night each in their home while sleep was recorded with polysomnography. For each device, participants also completed questionnaires to assess usability, mobility, perceived noise disturbance, and perceived sleep disturbance.
Study: NCT05607134

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: selected physical and occupational therapy program
Description: The children in this group will receive a selected physical and occupational therapy programs one hour three times weekly for eight successive weeks.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Radial Extracorporeal Shock Wave
Description: The children in this group will receive in addition to the selected physical therapy and occupational program as single session of shock wave intervention once per week for four eight successive weeks using (STORZ MEDICAL AG, Tagerwilen, Schweiz) device. rESWT will be applied on flexor carpi ulnaris, flexor carpi radialis, in the middle of the muscle belly and tendons of flexor digitorum on the palm. The treatment protocol of rESW will follow; 1500 shoots for each muscle; 0.030 mj/mm2; 4 HZ with pressure 1 bar will be used.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Peripheral magnetic stimulation
Description: The children in this group will receive in addition to the selected physical therapy program peripheral magnetic stimulation (PMS) therapy for twenty minutes, three sessions per week, for eight successive weeks using Peripheral magnetic stimulation device A MAGNUM XL Pro, Globus, Italia. The PMS consisted of 2000 stimuli at a stimulation frequency of 20Hz, a train duration of 1 second, and an intertrain interval of 2 seconds. Intensity was individually set at 10% to 100% of the maximum stimulus intensity.
Study: NCT06370754

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan Liposome Injection
Description: 60 or 70 mg/m\^2 by IV infusion every 2 weeks (Q2W), given on cycle day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan Liposome Injection
Description: 60 or 70 mg/m\^2 by IV infusion every 2 weeks (Q2W), given on cycle day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan Liposome Injection
Description: 60 or 70 mg/m\^2 by IV infusion every 2 weeks (Q2W), given on cycle day 1.
Study: NCT01179529

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omalizumab (Xolair®)
Study: NCT06167902

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ginseng oligopeptide (Ginseng extract）
Description: The experimental group was given ginseng oligopeptide preparation 1.2g per day orally.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Maltodextrin
Description: The control group was treated with placebo maltodextrin 1.2g/d
Study: NCT06410378

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: controll group
Description: patient will receive general anesthesia
Study: NCT06259162

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: LAG-3 expression / immune checkpoint protein expression
Description: Evaluate the tissue and blood before and after chemotherapy
Study: NCT06370754

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Fluorouracil (5-FU)
Description: 2400mg/m\^2, intravenously, over 46 h on day 1, Q2W.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Fluorouracil (5-FU)
Description: 2400mg/m\^2, intravenously, over 46 h on day 1, Q2W.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Fluorouracil (5-FU)
Description: 2400mg/m\^2, intravenously, over 46 h on day 1, Q2W.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin (LV)
Description: 400mg/m\^2, intravenously, over 30 min on day 1, Q2W.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin (LV)
Description: 400mg/m\^2, intravenously, over 30 min on day 1, Q2W.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin (LV)
Description: 400mg/m\^2, intravenously, over 30 min on day 1, Q2W.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab paclitaxel
Description: 125 mg/m\^2 by IV infusion Q3W, given on cycle day 1 and 8.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab paclitaxel
Description: 125 mg/m\^2 by IV infusion Q3W, given on cycle day 1 and 8.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab paclitaxel
Description: 125 mg/m\^2 by IV infusion Q3W, given on cycle day 1 and 8.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: 1000 mg/m\^2 by IV infusion Q3W, given on cycle day 1 and 8.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: 1000 mg/m\^2 by IV infusion Q3W, given on cycle day 1 and 8.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: 1000 mg/m\^2 by IV infusion Q3W, given on cycle day 1 and 8.
Study: NCT05143359

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Wharfe and Pederson difficulty index
Description: Efficiency of Wharfe and Pederson Difficulty index in extraction of third molars.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Winters difficulty index
Description: Efficiency of Winters Difficulty index in extraction of third molars.
Study: NCT05916911

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Glizigen
Description: Treatment initiation: Treatment should be started simultaneously with the appropriate oral and intravaginal formulation after the last menstrual period or immediately in menopausal patients.~A total of 60 single doses of intravaginal use and 60 doses of oral solution should be given to each patient.~The intravaginal gel should be applied every night before going to sleep by inserting the cannula completely into the vagina and pressing the tube until the entire contents of the tube are poured into the vagina, then removing the cannula from the vagina while continuing to press the tube to avoid retrograde aspiration of the product. Application of the intravaginal gel should be discontinued during days of menstrual bleeding.~The oral solution should be administered by drinking 1 vial every morning without interruption for 60 days from the start of treatment. It can be taken either on an empty stomach or with food.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Treatment initiation: Treatment should be started simultaneously with the appropriate oral and intravaginal formulation after the last menstrual period or immediately in menopausal patients.~A total of 60 placebo single doses of intravaginal use and 60 placebo doses of oral solution should be given to each patient.~The placebo intravaginal gel should be applied every night before going to sleep by inserting the cannula completely into the vagina and pressing the tube until the entire contents of the tube are poured into the vagina, then removing the cannula from the vagina while continuing to press the tube to avoid retrograde aspiration of the product. Application of the intravaginal gel should be discontinued during days of menstrual bleeding.~The placebo oral solution should be administered by drinking 1 vial every morning without interruption for 60 days from the start of treatment. It can be taken either on an empty stomach or with food.
Study: NCT06344611

Intervention type: OTHER
Intervention: Other
Description: It is an observational study. Subjects will receive the treatment as per institute protocol.
Study: NCT05521594

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fine Needle Aspiration Cytology
Description: Comparison between FNAC and post operative specimen after thyroid surgery
Study: NCT05523180

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic
Description: Active ingredients:~Lactobacillus plantarum RSB11, 5 Billion colony forming units (CFU) Lactobacillus acidophilus RSB12, 5 Billion CFU Lactobacillus rhamnosus RSB13, 5 Billion CFU Holy basil leaf extract, 42.0 mg Turmeric root extract, 30.0 mg Vasaka leaf extract, 48.0 mg~Inactive ingredients:~Microcrystalline Cellulose, Vegan Capsule (Hypromellose), Magnesium Stearate, Silicon Dioxide

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Active ingredients:~N/A~Inactive ingredients:~Microcrystalline Cellulose, Vegan Capsule (Hypromellose), Magnesium Stearate, Silicon Dioxide
Study: NCT01283737

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DBX Putty
Description: OCD of the knee will be treated with DBX Putty

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Mosaicplasty
Description: Mosaicplasty procedure performed to treat OCD of the knee
Study: NCT05435521

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Personalized multicomponent exercise program (strength, resistance, balance, and flexibility) (PMEP)
Description: Physical activity expert will design for each participant a personalized exercise program according to baseline situation and previous physical activity. Both will be measured prior to initiation of activity program. Each participant is free to perform physical activity program at his house, outdoor or in a gym as long as it fulfills the prespecified requirements. Exercise programs will be acquired a more personalized shape during the course of the study.~In order to motivate participants, personal motivational messages will be sent each week through mail contact or using WhatsApp Social Media.~Physical activity will be registered in an activity wristband delivered to each participant at baseline evaluation.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Personalized multicomponent exercise program (strength, resistance, balance, and flexibility) (PMEP)
Description: Physical activity expert will design for each participant a personalized exercise program according to baseline situation and previous physical activity. Both will be measured prior to initiation of activity program. Each participant is free to perform physical activity program at his house, outdoor or in a gym as long as it fulfills the prespecified requirements. Exercise programs will be acquired a more personalized shape during the course of the study.~In order to motivate participants, personal motivational messages will be sent each week through mail contact or using WhatsApp Social Media.~Physical activity will be registered in an activity wristband delivered to each participant at baseline evaluation.
Study: NCT05428618

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: e-BariS app group
Description: During the discharge process, informed consent will be obtained from the patients and the measurement tools will be filled and the mobile application will be downloaded to their phones. The intervention group will have access to all the content of the mobile application, which includes the Self-Monitoring Module and the Patient Education Module. Passwords will be defined so that patients in the intervention group can access the Patient Education Module. Information on the introduction and use of the application will be presented to the patient by the researcher.~The patients will be followed for six months within the scope of the project. In addition, reminder notifications will be sent to patients via the mobile application in line with the areas that patients can access. At one, three, and six months after surgery, he will complete other assessment scales during outpatient follow-up. For patients providing remote control, the scale will be sent online.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Self-Monitoring Group
Description: Patients in the control group will only have access to the Self-Monitoring Module in the application. Other fields will be encrypted. Patients in the control group will also be informed about the area they can access. Patients in the control group will only have access to the self-monitoring section. One, three, and six months after surgery, she will complete other assessment scales during her outpatient follow-up. Scales will be sent online for patients providing remote control. After the project is completed, all content will be opened to the control group patients.
Study: NCT06080815

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CAD/CAM Complete denture
Description: four implant-supported CAD/CAM complete overdenture

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CAD/CAM Complete denture
Description: four implant-supported CAD/CAM complete overdenture